ECS Botanics to Support UWA Clinical Trial on Medicinal Cannabis for Sleep Apnoea

ECS Botanics Holdings Ltd (ASX: ECS), a leading medicinal cannabis producer, will supply its GMP-manufactured Avani THC10 softgel capsules to a new clinical trial led by the University of Western Australia’s Centre for Sleep Science. The investigator-led trial, registered under ACTRN12624000572549, will evaluate the efficacy of 10mg THC in treating obstructive sleep apnoea (OSA) and its physiological impacts, including next-day cognitive and psychomotor effects. The randomised, double-blind, controlled trial will enrol 24 participants, with recruitment expected to commence in July 2025 and run throughout the year.

ECS Managing Director Nan-Maree Schoerie stated that the Company is committed to evidence-based approaches in medicinal cannabis and welcomes the opportunity to support rigorous academic research. The trial further aligns with ECS’s mission to promote science, sustainability, and transparency while advancing its therapeutic product portfolio in collaboration with clinicians, researchers, and regulatory bodies.

Customer Notice:

Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.

Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com